Case Study

Overcoming The Challenge Of Enrolling Sickle Cell Patients In Clinical Trials

Source: Premier Research
Business Group Meeting

Kick off a study of a drug to treat sickle cell disease and you’re facing a tough climb. Experimental drugs for sickle cell are few and far between, so there is little in the way of clinical trial infrastructure. The patient population is demographically challenging, too, made up largely of socioeconomically disadvantaged people who find it difficult to comply with the rigors of clinical drug trials.

That’s what made it so remarkable when we enrolled the first patient three weeks early in this Phase I open-label, dose-escalation trial of a drug to make hemoglobin more efficiently transport oxygen in sickle cell patients.